United States Hormone Refractory Prostate Cancer Market Expands at 6.2% CAGR as Targeted, Radioligand & Precision Therapies Transform CRPC Care

Leander, Texas, United States - Dec.17.2025
As per DataM Intelligence research report "Global Hormone Refractory Prostate Cancer Market is growing with a high 6.2% CAGR during the forecast period 2024-2031.". Increasing prevalence of prostate cancer, strong pipeline of innovative therapies, and advancements in targeted treatments are driving the development of effective solutions for hormone refractory (castration-resistant) prostate cancer.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/hormone-refractory-prostate-cancer-market?sindhuri

Hormone Refractory Prostate Cancer Market: Recent Industry Developments
United States: Recent Industry Developments
✅ In November 2025, Johnson & Johnson advanced its prostate cancer portfolio with expanded indications for targeted therapies in metastatic castration-resistant cases, enhancing patient access to precision medicine.
✅ In October 2025, Novartis expanded access to radioligand therapies like Pluvicto for earlier intervention in PSMA-positive metastatic castration-resistant prostate cancer patients.
✅ In September 2025, AstraZeneca progressed clinical trials for combination therapies targeting androgen receptor pathways in hormone-refractory prostate cancer.
✅ In August 2025, Bayer AG initiated new studies combining androgen inhibitors with novel agents for improved outcomes in advanced castration-resistant prostate cancer.

Japan: Recent Industry Developments
✅ In November 2025, Astellas Pharma Inc. expanded approvals and access for enzalutamide-based regimens in hormone-refractory prostate cancer, supporting Japan's aging population needs.
✅ In October 2025, Takeda Pharmaceutical collaborated on immunotherapy advancements for castration-resistant prostate cancer, focusing on Asian patient profiles.
✅ In September 2025, regional partners advanced multimodal AI-assisted diagnostics for early detection and management of hormone-refractory cases.
✅ In August 2025, Japanese institutions launched pilot programs integrating next-generation hormonal therapies with precision oncology approaches.

Hormone Refractory Prostate Cancer Market: Drivers
The hormone refractory prostate cancer market, also known as castration-resistant prostate cancer (CRPC), is experiencing significant growth due to the rising global incidence of prostate cancer, particularly in aging populations, and the progression to advanced stages resistant to initial androgen deprivation therapy. Advancements in novel treatments, including next-generation hormonal therapies, chemotherapy, immunotherapy, radioligand therapies, and targeted agents, are improving survival rates and quality of life. A robust pipeline of drugs, increased awareness, early screening, and supportive reimbursement policies in developed regions are further propelling adoption.
Collaborations between pharmaceutical companies, research institutions, and oncology centers are accelerating innovation in precision medicine, combination therapies, and biomarker-driven approaches. Growing investments in R&D, regulatory approvals for expanded indications, and the shift toward personalized treatments address unmet needs in metastatic and non-metastatic CRPC. With escalating prevalence, technological progress, and focus on delaying disease progression, the hormone refractory prostate cancer market is set for substantial expansion globally.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/hormone-refractory-prostate-cancer-market?sindhuri

Hormone Refractory Prostate Cancer Market: Major Players
AbbVie Inc., Acceleron Pharma, Inc., AB Science SA, AstraZeneca Plc, Astellas Pharma Inc., Sanofi S.A., Bayer AG, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Johnson and Johnson.

Segment Covered in the Hormone Refractory Prostate Cancer Market:
By Treatment Type
Chemotherapy (Cytotoxic agents) is expected to grow at the fastest CAGR, driven by advancements in agents for advanced disease. Hormonal therapy follows with strong adoption of anti-androgen agents, while radiation, surgery, and emerging immunotherapies gain traction.
By End-User
Hospitals hold the largest share due to advanced infrastructure, large patient volumes, and comprehensive care capabilities. Ambulatory care units and specialty centers are growing rapidly.

Regional Analysis
North America - Largest Share
North America dominates with high prevalence, advanced healthcare systems, rapid adoption of novel therapies, and strong presence of key players in the U.S.
Asia-Pacific - Fastest Growing
Asia-Pacific expands quickly due to rising incidence, improving diagnostics, government initiatives, and increasing access in countries like Japan, China, and India.
Europe - Significant Share
Europe grows steadily supported by regulatory approvals and focus on precision oncology.
South America - Emerging Share
South America advances with improving healthcare infrastructure.
Middle East & Africa - Growing Share
Middle East & Africa progress through investments in oncology care.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=hormone-refractory-prostate-cancer-market?sindhuri
(Purchase 2 or more Reports and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.